Creative Medical Technology Holdings, Inc. announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application. The patent is titled “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity.” Once granted, the patent will be in effect until at least 2040.
This patent allows a broad cell-based immunotherapy approach to treating Type 1 diabetes using the ImmCelz™ product, which includes supercharged T regulatory cells utilizing the company’s proprietary cell-free solutions. This program has been validated using cells from patients with Type 1 Diabetes, an autoimmune disease where the body's immune system attacks insulin-producing beta cells.
The issuance of this patent protects the integrity of Creative Medical Technology's intellectual property portfolio. The treatment of Type 1 Diabetes remains a primary focus for the company, as evidenced by its ongoing CREATE-1 clinical trial, and this allowance reflects the potential of its cell-based therapeutic platform to address multiple unmet medical needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.